Check-Cap Ltd

MBAI
About the company

Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology for the detection of precancerous colorectal polyps. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

Country: IsraelPrice: $2.06Market Cap: $31.4M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

3 / 13

NEUTRAL / FAIL

Median fair value

$3.42

+66.2% vs price

Models with upside

3 / 17

Positive margin of safety

Strongest signal

Models split on MBAI at $2.06 — fair values range $0.40–$42.38

Key risk

No clean pass — all 8 investors flag at least one growth criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedFAILFAILFAILNEUTRALFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of Safety+23.9%N/AN/AN/AN/AN/AN/A+50.2%N/A+95.2%N/A-413.8%N/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-04-27

Score computed: 2026-11-14

Where It Passes

  • Valuation models75% pass✓ 3✗ 1▾

    Models split on MBAI at $2.06 — fair values range $0.40–$42.38

    Graham fair value$2.70
    ✓Graham+23.9% margin vs $2.06
    Pabrai fair value$4.13
    ✓Pabrai+50.2% margin vs $2.06
    Marks fair value$42.38
    ✓Marks+95.2% margin vs $2.06
    Templeton fair value$0.40
    ✗Templeton-413.8% margin vs $2.06

Where It Falls Short

  • Growth0% pass✓ 1✗ 12▾

    No clean pass — all 8 investors flag at least one growth criterion

    EPS Growth (3-yr avg, 10-yr window)19.3%
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)P/E 3.1x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR-40.7%
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthN/A (no inventory)
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction$3.27 (2013) -> $0.66 (2025)
    ✗DremanPositive over recent years
    EPS CAGR-12.5% CAGR over 12 years
    ✗Dreman> 5% annualized
    Positive Net Income Frequency1/13 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth
    ✗Ackman>= 5%
    Positive EPS Growth Frequency1/5 years with positive EPS growth
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR-40.7% CAGR over 5 years
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trend
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR-40.7% over 5 years
    ✗Neff7%-20% annualized
  • Efficiency0% pass✗ 11▾

    All 8 investors flag MBAI's efficiency

    Current Ratio0.05
    ✗Graham>= 2.0
    ROIC (3-5 yr avg)
    ✗Buffett> 10%
    ROIC - WACC
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)
    ✗Greenblatt> 25%
    Current Ratio Change YoY0.15 -> 0.05
    ✗PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities0.05
    ✗Dreman> 1.5
    Return on Invested Capital
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)
    ✗SleepROIC > 12% in a majority of years
  • Verdicts0% pass✗ 13▾

    Split decision: 13 FAIL · 3 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (2/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (2/11)✗MungerFAIL (1/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (0/6)✗MarksFAIL (2/5)✗AckmanFAIL (1/9)✗TempletonFAIL (3/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
  • Debt & Leverage8% pass✓ 1✗ 14▾

    11 of 12 flag MBAI's debt & leverage — Graham, Buffett, Lynch +8 more

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest Coverage
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity
    ✗Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities0.05
    ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity
    ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
    Debt Levels
    ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDA
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity
    ✗Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)
    ✗AsnessTop 30% of eligible cross-section
  • Cash Flow10% pass✓ 1✗ 11▾

    9 of 10 flag MBAI's cash flow — Buffett, Lynch, Piotroski +6 more

    Free Cash Flow Proxy$-17.4M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-17.0M
    ✗LynchPositive and growing
    Operating Cash Flow$-0.0M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-0.61%, ROA=55.30%
    ✗PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldP/E=3.1x
    ✓PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive0/11 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap
    ✗Ackman>= 4%
    Price / FCF per Share
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency0/13 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization
    ✗OshaughnessyTop 10% of eligible cross-section
  • Profitability19% pass✓ 11✗ 24▾

    13 of 16 flag MBAI's profitability — Graham, Buffett, Lynch +10 more

    Positive EPS (10 years)13/14 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)19.3%
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)1/14 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-23.7%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-17.4M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)0.74
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)P/E 3.1x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR-40.7%
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE120.5%
    ✓Lynch> 15%
    EBIT / Enterprise Value-7.6%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-7.6%, ROC=None
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets55.30%
    ✓PiotroskiROA > 0
    ROA Change YoY-6670.82% -> 55.30% (delta: +6726.13%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-0.61%, ROA=55.30%
    ✗PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity120.5%
    ✓Dreman> 12%
    Margin of SafetyP/E=3.1x, P/B=4.2x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity0.0% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic Value94.8% (IV=$39.80 vs Price=$2.06)
    ✓Marks>= 20% below intrinsic value
    Positive Net Income Frequency1/13 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue
    ✗Ackman>= 15%
    Net Income / Shareholders Equity120.5%
    ✓Ackman>= 15%
    5-Year EPS CAGR-40.7% CAGR over 5 years
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend
    ✗TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trend
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization+13.17%; #437/6340 (top 6.9%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity+120.45%; #63/5226 (top 1.2%)
    ✓AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-26.5987; #5762/5884 (top 97.9%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR-40.7% over 5 years
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years10/10 years positive
    ✓Schloss>= 70% positive over 5-10 observed years (app rule)
  • Valuation23% pass✓ 12✗ 16▾

    10 of 13 flag MBAI's valuation — Graham, Lynch, Greenblatt +7 more

    Price / 3-yr avg EPS0.8x
    ✓Graham<= 15x
    Price-to-Book Ratio4.2x
    ✗Graham<= 1.5x
    P/E x P/B3.30
    ✓Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)P/E 3.1x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-7.6%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-7.6%, ROC=None
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS3.1x
    ✓Dreman< 12x✓Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per Share4.2x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessP/E=3.1x, OE Yield=28.7%
    ✓MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=3.1x
    ✓PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=3.1x, P/B=4.2x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic Value94.8% (IV=$39.80 vs Price=$2.06)
    ✓Marks>= 20% below intrinsic value
    Price / FCF per Share
    ✗Ackman<= 25
    Price vs. Trailing Low114% of trailing low ($1.80)
    ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization+13.17%; #437/6340 (top 6.9%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.1094; #4696/6449 (top 72.8%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS3.1x
    ✓NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share5.32x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-93.1%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-97.50%; #6094/6202 (top 98.3%)
    ✗OshaughnessyTop 10% of eligible cross-section

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Medical Equipment
SIC Sector: Measuring & Medical Instruments
Size: Micro Cap($31.4M)
Revenue: N/A
Net Income: $4.1M+116.5% YoY

Financial Snapshot

Operating Margin--
Return on Equity120.5%
Debt / Equity--
Current Ratio0.05
EPS (Diluted)$0.66
Shares Retired−20.0% / −20.0% 2y

Similar Companies

ALCALCON INC
$35.6B
PHGKONINKLIJKE PHILIPS NV
$29.7B
WSTWEST PHARMACEUTICAL SERVICES INC
$29.0B
SNNSMITH & NEPHEW PLC
$13.1B

Shareholder Return

Fiscal 2025

Issued 20.0% of shares last year, 20.0% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

MetricFY 2025
Sources
  • 20-F · 2026-04-27
FY 2024
Sources
  • 20-F · 2025-08-27
FY 2023
Sources
  • 20-F · 2025-08-27
FY 2022
Sources
  • 20-F · 2025-08-27
FY 2021
Sources
  • 20-F · 2022-04-06
Market Cap$31.4Mcurrent$5.3Mest.$12.3Mest.$17.8Mest.--
Revenue----------
Operating Income-$2.4M↑75%-$9.5M↑51%-$19.3M↑4%-$20.0M↓16%-$17.3M
Net Income$4.1M↑116%-$25.1M↓43%-$17.6M↑8%-$19.1M↓11%-$17.2M
EPS (Diluted)$0.66↓85%$4.30↑43%$3.00↓11%$3.37↓19%$4.14
Gross Margin—————
Operating Margin—————
ROE120.5%↓93%1734.4%↑2439%-74.2%↓60%-46.3%↓36%-33.9%
Total Debt----------
Shareholders' Equity$3.4M↑337%-$1.4M↓106%$23.7M↓43%$41.3M↓19%$50.7M
Current Ratio0.05↓63%0.15↓99%18.69↑49%12.51↓4%13.05
Debt / Equity—————
Operating Cash Flow-$46.0K↑99%-$8.0M↑53%-$17.0M↑9%-$18.7M↓15%-$16.3M
Free Cash Flow-----$17.0M↑11%-$19.2M↓11%-$17.3M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Medical Equipment

MBAI vs Peers — Financial Grading

RevenueN/A
Net Income$4.1MBottom 25%
ROE120.5%Top 25%
D/E—
Op. Margin—
Curr. Ratio0.05Bottom 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11